Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease;Estudio observacional sobre seguridad, tolerabilidad y efectividad de la galantamina en pacientes con enfermedad de Alzheimer leve a moderadamente grave

Neurologia

Volumn 21, Issue 6, 2006, Pages 289-296

  Blesa, Rafael ^a   Garcia Ribas G ^b   Galdos L ^c   Olascoaga, J ^d   Amer, G ^e   Marey Lopez J ^f   Barquero, M ^g   Marsall, C ^h   Ezpeleta, D ⁱ  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b JANSSEN CILAG GMBH   (Germany)

^c HOSPITAL TXAGORRITXU   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL VIRGEN DE LA SALUD   (Spain)

ⁱ Anatomía Patológica del Hospital Reina Sofía de Tudela   (Bulgaria)

Author keywords

Alzheimer's disease; Galantamine; Pharmacosurveillance; Safety; Tolerability

Indexed keywords

GALANTAMINE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ANNOYANCE; ANOREXIA; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; SCORING SYSTEM; SIDE EFFECT; SLEEP; SPAIN; SYNCOPE; TITRIMETRY; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; COMORBIDITY; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED;

EID: 33746434361     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pendlebury WW, Solomon PR. Alzheimer's disease. Clin Symp 1996;48:2-32.
2. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
3. Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 1999;12:35-48.
4. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000;54:447-51.
5. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 2000;54:2072-7.
6. Kawas CH, Brookmeyer R. Aging and the public health effects of dementia. N Engl J Med 2001;344:1160-1.
7. Jorm AF, Jolley D. The incidence of dementia: a metaanalysis. Neurology 1998;51:728-33.
8. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-6.
9. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003;10:633-40.
10. Proskurnina NF, Yakovleva AP. Alkaloids of Galanthus Woronowi. J Gen Chemi USSR 1952;22:1941-4.
11. Baraka A, Harik S. Reversal of central anticholinergic syndrome by galanthamine. JAMA 1977;238:2293-4.
12. Lopez S, Bastida J, Viladomat F, Codina C. Acetylcholinesterase inhibitory activity of some Amaryllidaceoe alkaloids and Narcissus extracts. Life Sci 2002;71:2521-9.
13. López S, Bastida J, Viladomat F, Codina C. Galanthamine pattern in Narcissus confusus plants. Planta Med 2003;69:1166-8.
14. Szewczyk J, Lewin AH, Carroll FI. An improved synthesis of (+/-)-, (+)-, and (-)-galanthamine. J Heterocyclic Chem 1995;32:195-9.
15. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998;19:465-80.
16. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000;393:165-70.
17. Arroyo G, Aldea M, Fuentealba J, Garcia AG. Receptor nicotinico, galantamina y enfermedad de Alzheimer. Rev Neurol 2002;34:1057-65.
18. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al.; GAL-GBR-2 Study Group. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-89.
19. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76.
20. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004;61:252-6.
21. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
22. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with «advanced moderate» Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003;15:79-87.
23. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract 2003;57:219-23.
24. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-8.
25. Marcusson J, Bullock R, Gauthier S, Kurz A, Schwalen S. Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17 (Suppl. 3):S86-S91.
26. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283-90.
27. Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs 2003;17:905-14.
28. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, GAL-INT-6 Study Group. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765-82.
29. Bullock R, Erkinjuntti T, Lilienfeld S, GAL-INT-6 Study Group. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004;17:29-34.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
31. Lobo A, Ezquerra J, Gómez Burgada F, Sala JM, Seva Diaz A. El Mini-Examen Cognoscitivo (un test sencillo, práctico, para detectar alteraciones intelectivas en pacientes médicos). Actas Luso Esp Neurol Psiquatr 1979;7:189-202.
32. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-9.
33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
34. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
35. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824-9.
36. Galasko D, Corey-Bloom J, Thai LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 1991;39:932-41.
37. Schneider LS. Tracking dementia by the IMC and the MMSE. J Am Geriatr Soc 1992;40:537-8.
38. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999;56:857-62.
39. Alberca R. Manifestaciones clínicas de la enfermedad de Alzheimer. En: Alberca R, López-Pousa S, editores. Enfermedad de Alzheimer y otras demencias. Madrid: Editorial Médica Panamericana, 2002; p. 233-50.
40. Alberca R. Tratamiento farmacológico de la enfermedad de Alzheimer. En: Alberca R, López-Pousa S, editores. Enfermedad de Alzheimer y otras demencias. Madrid: Editorial Médica Panamericana, 2002; p. 309-25.
41. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11(Suppl. 1):28-34.
42. Blesa R. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease. Alzheimer Dis Assoc Disord 2004;18(Suppl. 1):S9-S16.
43. Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G. Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. Sleep 2003;26:602-6.